Case of severe acneiform eruptions associated with the BRAF inhibitor vemurafenib

被引：5
|
作者：
Ansai, Osamu [1 ]
Fujikawa, Hiroki [1 ]
Shimomura, Yutaka [1 ]
Abe, Riichiro [1 ]
机构：
[1] Niigata Univ, Grad Sch Sci & Technol, Div Dermatol, Chuo Ku, 1-757 Asahimachi dori, Niigata 9518510, Japan
来源：
JOURNAL OF DERMATOLOGY | 2017年 / 44卷 / 03期
关键词：
METASTATIC MELANOMA;
D O I：
10.1111/1346-8138.13534
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E15 / E16
页数：2
相关论文
共 50 条
  • [31] BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy
    Koya, Richard C.
    Mok, Stephen
    Otte, Nicholas
    Blacketor, Kevin J.
    Comin-Anduix, Begonya
    Tumeh, Paul C.
    Minasyan, Aspram
    Graham, Nicholas A.
    Graeber, Thomas G.
    Chodon, Thinle
    Ribas, Antoni
    CANCER RESEARCH, 2012, 72 (16) : 3928 - 3937
  • [32] Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection
    Sondermann, Wiebke
    Griewank, Klaus G.
    Schilling, Bastian
    Livingstone, Elisabeth
    Leyh, Julia C.
    Rompoti, Natalia
    Cosgarea, Ioana
    Schimming, Tobias
    Schadendorf, Dirk
    Zimmer, Lisa
    Hillen, Uwe
    PLOS ONE, 2015, 10 (04):
  • [33] Erythema nodosum, an uncommon cutaneous side effect of the BRAF inhibitor, Vemurafenib
    Robinson, D.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2013, 54 : 16 - 16
  • [34] BRAF inhibitor (vemurafenib) resistance confers sensitivity to arginine deprivation in melanoma
    Li, Ying-Ying
    Wu, Chunjing
    Chen, Shu-Mei
    Wangpaichitr, Medhi
    You, Min
    Spector, Seth
    Feun, Lynn G.
    Kuo, Macus T.
    Savaraj, Niramol
    CANCER RESEARCH, 2014, 74 (19)
  • [35] Cutaneous Toxic Effects Associated With Vemurafenib and Inhibition of the BRAF Pathway
    Huang, Victor
    Hepper, Donna
    Anadkat, Milan
    Cornelius, Lynn
    ARCHIVES OF DERMATOLOGY, 2012, 148 (05) : 628 - 633
  • [36] Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy
    DeWitt, Christine A.
    Siroy, Alan E.
    Stone, Stephen P.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (03) : 500 - 505
  • [37] Ocular changes in metastatic melanoma patients treated with MEK inhibitor cobimetinib and BRAF inhibitor vemurafenib
    Gavric, Ana Ursula
    Ocvirk, Janja
    Mekjavic, Polona Jaki
    RADIOLOGY AND ONCOLOGY, 2018, 52 (02) : 213 - 219
  • [38] Hair changes associated with BRAF inhibitor therapy: a case series
    Fitzgerald, M.
    Fearfield, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 : 92 - 92
  • [39] EGFR Inhibitor-Associated Acneiform FolliculitisAssessment and Management
    Madeleine Duvic
    American Journal of Clinical Dermatology, 2008, 9 : 285 - 294
  • [40] Case History: Vemurafenib, a Potent, Selective, and First-in-Class Inhibitor of Mutant BRAF for the Treatment of Metastatic Melanoma
    Ibrahim, Prabha N.
    Zhang, Jiazhong
    Zhang, Chao
    Bollag, Gideon
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 48, 2013, 48 : 435 - 449
12345